Weiss Law reminds shareholders of SBTX, LJPC, CNVY and DRE of its ongoing investigations

NEW YORK, July 28, 2022 /PRNewswire/ —

If you hold shares in any of the companies listed above and
want to discuss our surveys or have questions about
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Silverback Therapeutics, Inc. (NASDAQ: SBTX)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Silverback Therapeutics, Inc. (NASDAQ: SBTX), in connection with SBTX’s proposed merger with ARS Pharmaceuticals, Inc. (“ARS”). Under the terms of the merger agreement, assuming SBTX’s net cash at closing is $240 million, SBTX shareholders are expected to own approximately 37% of the combined company and ARS shareholders prior to the merger are expected to own approximately 63% of the combined company. If you own SBTX stock and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/sbtx

La Jolla Pharmaceutical Company (NASDAQ: LJPC)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of La Jolla Pharmaceutical Company (NASDAQ: LJPC) in connection with the proposed acquisition of LJPC by Innoviva, Inc. via a tender offer. Under the terms of the merger agreement, LJPC shareholders will receive $6.23 in cash for each common share of LJPC held. If you own LJPC stock and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/ljpc

Transmit Health Solutions Holdings, Inc. (NYSE: CNVY)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Transmit Health Solutions Holdings, Inc. (NYSE: CNVY), in connection with the proposed acquisition of CNVY by TPG Capital. Under the terms of the merger agreement, CNVY shareholders will receive $10.50 in cash for each common share of CNVY held. If you own CNVY stock and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/cnvy

Duke Realty Corporation (NYSE: DRE)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Duke Realty Corporation (NYSE: DRE), in connection with the proposed acquisition of DRE by Prologis, Inc. (“Prologis”). Following the transaction, DRE shareholders will receive 0.475 common shares of Prologis for each DRE share held, representing an implied merger consideration per share of approximately $60.51 based on Prologis July 27, 2022 closing price of $127.39. If you own DRE stock and would like to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/dre

SOURCE Weiss’ Law

Comments are closed.